# 2018

Montreux, Switzerland

I-01 Annika SchneiderPhysiologically based pharmacokinetic modeling – application for renal and hepatic impairmentWednesday 10:10-11:40 |

I-02 Johannes SchroppCharacterization of bispecific antibodies and the ternary complex including an optimal dosing strategy Wednesday 10:10-11:40 |

I-03 Pascal SchulthessFrequency-domain derived optimisation of cell cycle specific cancer treatmentWednesday 10:10-11:40 |

I-04 Bernard SebastienHypoglycemic risk kinetics modeling as patient achieving glucose control in insulin-naïve T2DM patients initiating glargine 300U/mL versus glargine 100U/mL Wednesday 10:10-11:40 |

I-05 Malte Selch LarsenImpact of trial designs, study conditions and statistical methods on the estimation of drug potency and power in clinical trials of haemophilia with inhibitorsWednesday 10:10-11:40 |

I-06 Jérémy SeuratRobust designs accounting for model uncertainty in longitudinal studies with binary outcomesWednesday 10:10-11:40 |

I-07 Shringi SharmaA Joint Model to Evaluate the Relationship between Lymph Node Response and Progression-Free Survival in Chronic Lymphocytic LeukemiaWednesday 10:10-11:40 |

I-08 Dmitry ShchelokovA semi-mechanistic model of targeted therapy for melanomaWednesday 10:10-11:40 |

I-09 Yucheng ShengItem response theory modelling of motor scores to investigate feasibility of reducing proof-of-concept trial for Parkinson’s diseaseWednesday 10:10-11:40 |

I-10 Christian SiebelConsensus on doxorubicin dosing in infants and children: pharmacokinetic simulations and Delphi processWednesday 10:10-11:40 |

I-11 Alena SimalatsarPersonalised delivery rate computation for intravenously administered anesthetic using Kalman filterWednesday 10:10-11:40 |

I-12 Erik SjögrenBridging physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PopPK) analyses in paediatric drug development: A case study based on intravenous esomeprazole Wednesday 10:10-11:40 |

I-13 Mike K SmithImplementing “best practice” in Pop PK modelingWednesday 10:10-11:40 |

I-14 Tom SnowdenA comparison of two model reduction methodologies for a QSP bone biology system with denosumab dosing.Wednesday 10:10-11:40 |

I-15 Victor SokolovEvaluation of the utility and efficiency of MATLAB and R-based packages for the development of quantitative systems pharmacology modelsWednesday 10:10-11:40 |

I-16 Eunjung SongBayesian estimation of parameters in the pharmacokinetic modelWednesday 10:10-11:40 |

I-17 Felix StaderA population database for elderly to inform physiologically-based pharmacokinetic models considering anatomical, physiological and biological system parametersWednesday 10:10-11:40 |

I-18 Konstantinos StamatopoulosA Population based PBPK Modelling for the Prediction of Bile Salts Disposition within GI Luminal Fluids – Towards a Mechanistic Bile Salts ModelWednesday 10:10-11:40 |

I-19 Andrew SteinGuiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systemsWednesday 10:10-11:40 |

I-20 Mark StrohCustomizing the distribution of a masked, tumor-activated antibody with quantitative systems pharmacology Wednesday 10:10-11:40 |

I-21 Sabine StueblerSystems biology model of the mucosal immune system in the context of inflammatory bowel diseaseWednesday 10:10-11:40 |

I-22 Claudia SuenderhaufThe Basel Phenotyping Capsule as a tool for Quantifying Human metabolism in vivo – a tool to personalize physiological and semiphysiological ModelsWednesday 10:10-11:40 |

I-23 Elin SvenssonMeta-analysis of rifampicin exposure and mortality in three randomized controlled phase II tuberculosis meningitis trialsWednesday 10:10-11:40 |

I-24 Robin SvenssonThe value of model-based therapeutic drug monitoring in tuberculosis treatment – optimized target for rifampicinWednesday 10:10-11:40 |

I-25 Elisa TacconiModel-based analysis for the screening and ranking of compounds against Plasmodium FalciparumWednesday 10:10-11:40 |

I-26 Chong TangPopulation Pharmacokinetics of Tacrolimus in Pediatric Patients having undergone kidney, liver or bowel/liver transplantation.Wednesday 10:10-11:40 |

I-27 Lénaïg TanneauBedaquiline appears to antagonize its own main metabolite’s QTcF interval prolonging effectWednesday 10:10-11:40 |

I-28 Sonya ChapmanDose Fractionation Study Design and PK/PD Model Analysis to Establish the Quantitative Pharmacology of Selective Aurora A Kinase Inhibition by Compound X and LY3295668Wednesday 10:10-11:40 |

I-29 Nadia TerranovaThe CICIL tool: a Java-based user-friendly application for the analysis of individual tumor size lesion dynamicsWednesday 10:10-11:40 |

I-30 Adrien TessierPopulation pharmacokinetics in adults and model-based extrapolation and dose selection in the paediatric DMD population for drug S48168/ARM210Wednesday 10:10-11:40 |

I-31 Mita ThaparPopulation pharmacokinetic and exposure-lymphocyte analysis of FTY720 (Fingolimod/Gilenya) in pediatric patients with Multiple SclerosisWednesday 10:10-11:40 |

I-32 Pauline ThemansPrediction of meropenem systemic and infection site exposure and open-loop control strategy for optimal drug dosing: a PBPK approachWednesday 10:10-11:40 |

I-33 Tjokosela TikisoTB/HIV co-treatment with superboosted lopinavir lowers abacavir concentrations in children Wednesday 10:10-11:40 |

I-34 Tom HaberDiffMEM: an open-source package for high-performance pharmacometric model estimationWednesday 10:10-11:40 |

I-35 Elena ToscaIn vitro-in vivo correlation (IVIVC) population modeling for the in silico bioequivalence of a long-acting release formulation of Progesterone. Wednesday 10:10-11:40 |

I-36 Kota ToshimotoApplication of virtual clinical studies to predict the effect of inter-individual differences on the drug/metabolites exposures in the blood and target organs leading to different pharmacological and toxicological effectWednesday 10:10-11:40 |

I-37 Pauline TraynardNew library of time-to-event (TTE) models for the MonolixSuite and application to two experimental data setsWednesday 10:10-11:40 |

I-38 Iñaki F. TrocónizAn immune quantitative framework for Hepatitis B viral infectionWednesday 10:10-11:40 |

I-39 Denise FeickPhysiologically-based pharmacokinetic modeling of gemfibrozil drug-drug interactions with the CYP2C8 victim drugs repaglinide and pioglitazone Wednesday 10:10-11:40 |

I-40 Sami UllahPopulation pharmacokinetic analysis of piperacillin in acute haemorrhagic stroke patients - a cerebral microdialysis studyWednesday 10:10-11:40 |

I-41 Chakradhara Rao Satyanarayana UppugunduriPopulation pharmacokinetic model for individualized busulfan dosing in children: Annexation to the existing vast list of PopPK models for performance evaluationWednesday 10:10-11:40 |

I-42 Piet van der GraafSystems pharmacology modelling of the alternative pathway to study target suitabilityWednesday 10:10-11:40 |

I-43 Louvina van der LaanPharmacokinetics of intracellular stavudine-triphosphate in children after reduced-dose: can we improve stavudine’s safety profile?Wednesday 10:10-11:40 |

I-44 Michiel Van EsdonkPopulation pharmacokinetic/pharmacodynamic analysis of multiple nociceptive pain models following a single oral pregabalin dose administration to healthy subjectsWednesday 10:10-11:40 |

I-45 Erno van SchaickSimulations of the paliperidone pharmacokinetics of intramuscular long-acting injectable microsuspensions of paliperidone palmitate in rats using a mechanistic modelWednesday 10:10-11:40 |

I-46 Tamara van SteegDevelopment of a mathematical model to elucidate the cross-linking of GSK-057 and ADAs and binding to TNFR1 receptor – filling the gap between hypothesis and reality. Wednesday 10:10-11:40 |

I-47 Rob van WijkNanoscale blood sampling from zebrafish larvae for the estimation of distribution volume and absolute clearanceWednesday 10:10-11:40 |

I-48 Marc VandemeulebroeckeGraphical Principles Cheat SheetWednesday 10:10-11:40 |

I-49 Diego VeraDisease modelling of repeated acute attacks in an acute intermittent porphyria mouse modelWednesday 10:10-11:40 |

I-50 Swantje VöllerUse of second-to-second physiological monitoring data for continuous evaluation of pharmacotherapy in preterm infants: an application to the respiratory stimulant doxapramWednesday 10:10-11:40 |

I-51 Veronika VoronovaUsing a physiologically-based QSP model to simulate the effects of perturbations of the enterohepatic circulation of bile acids Wednesday 10:10-11:40 |

I-52 Johan WallinValidation of Xenograft Dose Predictions for Clinical Efficacy in NSCLCWednesday 10:10-11:40 |

I-53 Evan WangModel-based assessment of QT interval correction methodsWednesday 10:10-11:40 |

I-54 Shijun WangA comparison between nonlinear mixed effects and naïve pooled data methods in population PK model selectionWednesday 10:10-11:40 |

I-55 Roeland WasmannNormal fat mass cannot be reliably estimated in typical pharmacokinetic studiesWednesday 10:10-11:40 |

I-56 Sebastian WeberSupporting drug development as a Bayesian in due time?!Wednesday 10:10-11:40 |

I-57 Sebastian WichaHandling inter-occasion variability in model implementation for Bayesian forecasting: A comparison of methods and metrics.Wednesday 10:10-11:40 |

I-58 Mélanie WilbauxRisk score based on survival multivariate analysis of baseline patients’ characteristics reduces variability in a PKPD model of tumor growth inhibitionWednesday 10:10-11:40 |

I-59 Justin WilkinsPopulation pharmacokinetic analysis of M7824 (MSB0011359C) in different cancer typesWednesday 10:10-11:40 |

I-60 Francis Williams OjaraA time-to-event analysis of paclitaxel-related peripheral neuropathy in patients with advanced non-small cell lung cancer receiving first line chemotherapyWednesday 10:10-11:40 |

I-61 Dan WrightIdentifying systematic bias in model predictions Wednesday 10:10-11:40 |

I-62 Liviawati WuPopulation Pharmacokinetics and Dosing Simulation of JNJ-64155806 (AL-794) in Healthy VolunteersWednesday 10:10-11:40 |

I-63 Gudrun WuerthweinPopulation pharmacokinetics for PEGylated asparaginase Oncaspar® in children with ALL: differences between protocol parts and predictivityWednesday 10:10-11:40 |

I-64 Xia LiPopulation pharmacokinetics of ciprofloxacin in critically ill patients-a covariate analysisWednesday 10:10-11:40 |

I-65 Feifan XieA model-based analysis of the kinetics of leukocytes in stage III ovarian cancer patients treated with neo-adjuvant chemotherapy, cytoreductive surgery and cisplatin-based intraperitoneal chemoperfusionWednesday 10:10-11:40 |

I-66 James YatesStructural Identifiability for Mathematical Pharmacology: Models of myelosuppressionWednesday 10:10-11:40 |

I-67 Jinqiu YinOptimizing treatment of cephalosporin-resistant pneumococcal meningitisWednesday 10:10-11:40 |

I-68 Gunnar YngmanLinearization of full random effects modeling (FREM) for time-efficient automatic covariate assessmentWednesday 10:10-11:40 |

I-69 Jurij Aguiar ZdovcThe expression of ABCB1 gene influences the PK of rivaroxaban – a PK/PD study in patients with the total hip or knee arthroplastyWednesday 10:10-11:40 |

I-70 Nan ZhangCreation of Pharmacometric Framework to Evaluate Clinical Trial Data on Predictive BiomarkersWednesday 10:10-11:40 |

I-71 Ying ZhangExposure–Response Model and Development of a Shiny App of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients with Hereditary Angioedema (HAE)Wednesday 10:10-11:40 |

I-72 Fan ZhangStructural and Practical Considerations in the Development of a Parent-metabolite ModelWednesday 10:10-11:40 |

I-73 Xiaoyan ZhangPopulation pharmacokinetic/pharmacodynamic modeling of plasma lyso-sphingomyelin response to enzyme replacement therapy olipudase alfa in patients with acid sphingomyelinase deficiency Wednesday 10:10-11:40 |

I-74 Li ZhangMechanism-based Population PK/PD modeling of T lymphocytes Depletion and Repopulation Following Treatment with anti-CD52 Antibody GLD52 in Patients with Progressive Multiple Sclerosis Wednesday 10:10-11:40 |

I-75 Chenyan ZhaoQuantification and prediction of the combined effect of minocycline and polymyxin B on multidrug-resistant Klebsiella pneumoniae Wednesday 10:10-11:40 |

I-76 Meng ZhaolingReal World Evidence and Model-informed Drug Development – an antidiabetic drug cardiovascular outcome case study Wednesday 10:10-11:40 |

I-77 Yi ZhengEffect of pregnancy on raltegravir free concentrationsWednesday 10:10-11:40 |

I-78 Xiao ZhuApplication of pharmacometrics to stimulus response models to describe signalling profiles of the cannabinoid-1 receptorWednesday 10:10-11:40 |